Patients affected by the ongoing Bundibugyo Ebola outbreak in the Democratic Republic of the Congo have been enrolled in a major international clinical trial aimed at testing potential life-saving treatments, health authorities have announced.
The study, known as the PARTNERS trial, is the first of its kind to evaluate experimental therapies specifically targeting the Bundibugyo strain of the Ebola virus, for which no approved treatment currently exists.
In a statement shared with the Ghana News Agency by the World Health Organisation (WHO) and its partners, researchers said the trial will assess the safety and effectiveness of promising antiviral drugs while ensuring that all participants receive comprehensive supportive medical care.
The statement described the initiative as a significant breakthrough in global efforts to improve survival rates and strengthen preparedness for future Ebola outbreaks.
According to the WHO, the current outbreak has so far recorded more than 1,400 confirmed cases, nearly 440 deaths, and about 210 recoveries.
Participants in the trial are receiving intensive supportive care, including intravenous fluids, oxygen therapy, pain management, and continuous clinical monitoring, alongside the experimental treatments being evaluated.
Health experts say conducting such research during an active outbreak is critical, as it allows for the rapid generation of evidence needed to improve treatment outcomes in real time.
The WHO noted that data from the trial could help identify safe and effective therapies, reduce mortality during the ongoing outbreak, and strengthen global response systems for future Ebola emergencies.
Findings from the study are also expected to inform future treatment guidelines and enhance international collaboration in the fight against Ebola virus disease.
